Annoviant recently announced it was awarded a $2.99 million National Institutes of Health grant to advance its TxGuard pulmonary-valved conduit for pediatric heart disease. The grant, an SBIR Phase 2 b grant, will help the Atlanta-based company accelerate the development and commercialization of its technology. It builds upon the company’s previous Phase 2 NIH grant […]
Annoviant
NIH funds Annoviant heart implant materials tech that can grow with children
Annoviant announced today that it received a $1.85 million NIH grant to help further the development and commercialization of its TxGuard. Atlanta-based Annoviant’s latest grant for the TxGuard pulmonary-valved conduit represents a continuation of the Phase I Small Business Technology Transfer (STTR) grant the company received in 2019, according to a news release. Get the full […]